The company will use its biotechnology to expand into the fertility industry, adding a new dimension to its portfolio.
These innovative fertility checks for men and women involve in-depth physical and biological evaluations, with 110 tests carried out, including Randox's DNA-based protein testing, run on patented biochip array technology, which permits simultaneous testing of multianalytes. The results provide a blueprint of health of the entire body, assessing its preparedness for conception and pregnancy.
Randox MD Dr Peter FitzGerald calls this a pioneering approach to fertility. As he explained, about one in six couples in the UK has difficulty conceiving. Research and experience of scientists has shown that this is not always because of a problem with the sperm, eggs and reproductive organs. Problems in other parts of the body may have a significant impact on fertility, from hormone imbalance, obesity and stress, he noted.
FitzGerald further explained that the Randox team is using the latest medical and scientific techniques available to assess the whole body, to provide clarity and to help boost fertility. He also noted that, for many couples, very sophisticated treatment, such as IVF, is not always needed and sometimes even a simple change in lifestyle or diet is enough.
The new fertility health checks are being launched via Randox's healthcare division Randox Health, in partnership with UK fertility experts from GCRM Belfast.
According to Dr Peter McFaul of GCRM Belfast, the new service will provide people thinking of having a baby with new investigative options. He expressed faith that Randox, in collaboration with GCRM Belfast, will bring an unrivalled and complete fertility service to Northern Ireland and the UK, from the first stages of planning a family, through to the treatment of infertility.
The announcement of the new service comes as international fertility experts gather in Northern Ireland for the Reproductive Health Conference taking place today and being led by Randox Health.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia